News
Eli Lilly, weight loss
Digest more
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, Lilly’s chief scientific officer. “The safety, tolerability, and efficacy were ...
Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...
Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to ...
All of them said they are still seeing intense demand for weight-loss medicines. Yet many of their patients cannot get health insurance coverage for the Lilly and Novo drugs, whose list prices ...
With strong cash flows derived from a stable and diversified product portfolio, Eli Lilly remains on solid financial footing. We expect the company's debt/EBITDA level to fall from close to 1.9 ...
The company's weight loss drug Zepbound also beat estimates, booking $2.31 billion in sales for the quarter. That more than quadrupled the $517.4 million that the treatment brought in a year ...
24/7 Wall St. on MSN1d
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback